Reimagining Clinical Trials for Remote Populations

Decentralized clinic trials are more than a mere trend, they are a revolution in the ways we support, reach and retain populations of patients historically known to have been left out. For decades, clinical trials have revolved around traditional, site-based models, with urban hospitals and research centers that required patients to travel, sometimes for hours, to reach them.

This approach, while familiar, has inevitably always excluded much of the population, such as those living in rural areas, those too unwell to travel frequently, and those who simply cannot afford the logistical and emotional cost of repeated visits.

By using wearable sensors, digital apps, and home-based care, patients can now contribute data from their own environments, at times that suit them. This is particularly important in remote settings, where access to specialist centers is limited.

The development of digital tools and wearable sensors, along with real-time data collection and a growing commitment to patient centricity, has propelled a shift toward decentralized clinical trials (DCTs). The impact of this shift has been most significant in rural areas, where DCTs offer the chance to participate in life-changing research from the comfort of home.

The integration of real-world data, captured through devices such as wearables and smart sensors, combined with traditional patient-reported outcomes (PROs), are driving this shift. When used effectively, this combination doesn’t just offer researchers a clear view of how treatments perform in the real world, it can also dramatically improve the patient experience, reduce dropout rates, and make the clinical trials process more inclusive, efficient, and humane.

The Real Cost of Participation: Retention at a Crisis Point

Clinical trials are more complex today than ever before. Over the past 15 to 20 years, the number of data points collected in a typical trial has skyrocketed.

Each new data point has the potential to deliver insight, but as a patient, it often means a myriad of appointments, apps, and more exhaustion. That cost is often paid by the patient, who is asked to travel more frequently to trial sites, stay longer during a visit, interact with a growing number of clinicians and coordinators, and often learn to use multiple devices or platforms simply to comply with protocol requirements.

For someone living five hours away from a clinical trial site or managing an advanced illness, this burden can quickly become unsustainable. Many patients drop out not because treatment is failing, but because the process is often overwhelming, confusing, and impractical.

If a patient’s data is incomplete, it cannot be used in final analysis, meaning that the study must either continue enrolling or extend its duration, increasing cost, complexity, and timelines.

In therapeutic areas such as oncology and rare disease, the problem is even more acute. In cancer trials, for example, patients who suspect that they are not receiving the experimental treatment—particularly if symptoms don’t improve—may disengage. Rare disease trials face recruitment challenges from the very beginning because patient populations are small and often geographically dispersed.

In contexts such as these, the traditional site model breaks down. Without fundamentally rethinking how trials are designed, many studies will simply fail to find and keep the people that they need.

Beyond Trial Sites: How Remote Data and Patient Voices are Changing the Game

A DCT does not remove care, rather, it brings care to the patient. Imagine being 200 miles from the nearest treatment location and having care brought to you.

This goes beyond convenience and offers a new way of operating. By using wearable sensors, digital apps, and home-based care, patients can now contribute data from their own environments, at times that suit them. This is particularly important in remote settings, where access to specialist centers is limited.

Furthermore, the integration of sensor-based, objective data with subjective patient-reported outcomes opens up a more nuanced, real-time picture of a patient’s response to treatment. Sensors can continuously monitor physiological metrics like heart rate variability, sleep quality, physical activity, or skin temperature.

Combined with digital diaries and surveys that record how patients actually feel, including pain levels, mood, energy, or cognitive symptoms, researchers can connect the dots between how treatments affect a patient both physically and mentally.

Importantly, digital tools also remove the reliance on retrospective memory. In traditional paper-based data collection conducted at a trial site, patients might be asked how they felt two weeks ago, which is a method prone to error or bias. In contrast, electronic clinical outcome assessments (eCOA) allow for immediate input—often with notification reminders—making the data more accurate, increasing its reliability, but also less taxing for patients.

The COVID pandemic accelerated the uptake of decentralized trial models, but also exposed their limitations. Too often, clinical visits were replaced with apps without lightening the patient’s load.

Modern trials that get it right don’t just shift the work, they ensure the solution simplifies life for patients as well. The burden was ultimately taken off the site and pushed onto the patient. Instead, technology should simplify, not complicate.

The best decentralized trials now focus on designing with the patient, not just for the patient. Tools are being co-created in patient design studios, in which real participants provide feedback on usability, clarity, and convenience.

One such case involving a redesigned digital consent form showed measurable improvements in both comprehension and compliance. Small design choices, such as how notifications are delivered or how questions are worded, can make a meaningful difference in keeping participants engaged over the long term.

Flexibility, Choice and Trust: Foundations for Long-Term Engagement

Patient retention isn’t just a metric, it’s a reflection of how valued and supported patients feel throughout the clinical trial process. While decentralized tools can help, the basis of retention lies in flexibility and trust.

Participation in clinical trials should not be about telling patients how to participate, instead, health researchers should collaborate and ask patients about their needs. It’s about building trust.

It could be virtual, hybrid or even on site, choice builds trust, and that trust keeps patients in the trial. Offering multiple methods of participation helps patients engage in a way that feels safe, manageable, and aligned with their day to day lives.

Aside from flexibility, patients want transparency. A repeated issue raised among participants was that they rarely, if ever, get to see their own data.

Gradually, this is starting to change, as sponsors are beginning to realize the value of returning information to participants. This kind of reciprocity reinforces the idea that trial participation is more of a partnership than a transaction.

While much of the recent focus has been on patients, site engagement also plays a critical role. Many clinicians have grown wary of research roles because of the sheer volume of new technology and administrative burden.

If sites feel unsupported or overwhelmed, their ability to support patients suffers too. Encouragingly, there’s a growing focus on the importance of site-centricity, in which tools are designed not only to collect data, but to streamline the clinician’s role and enable consistent patient interaction.

Looking to the Future: Patient-Centered Trials as a Strategic Imperative

As the industry continues to evolve, there’s a growing consensus that decentralization is not a temporary fix, but the foundation of future trial design. The medium-term outlook for retention remains mixed.

Some budget lines tied to patient experience or engagement have been reduced in favor of core operations, which suggests that the link between patient-centricity and trial success is still not universally accepted. However, those leading the charge are showing that a more empathetic, data-rich, and flexible approach can work.

As digital tools become more intuitive and integrated, the benefits of combining sensor data with patient-reported outcomes will continue to grow.

We are not just seeing a shift, we are seeing a reconfiguration of the status quo. It is imperative for trials to serve patients first or face losing them entirely in the process.

It’s not about eliminating in-person visits or replacing clinicians with apps, but about building systems that fit into people’s lives, especially those for whom traditional models were never designed. Decentralized trials act as a bridge for communities that have historically been left out of research.

By doing so, they give these patients a chance to be involved in shaping the future of medicine.

Reimagining Clinical Trials for Remote Populations

The Real Cost of Participation: Retention at a Crisis Point

Beyond Trial Sites: How Remote Data and Patient Voices are Changing the Game

Flexibility, Choice and Trust: Foundations for Long-Term Engagement

Looking to the Future: Patient-Centered Trials as a Strategic Imperative

Newsletter